Short Interest in MIRA Pharmaceuticals, Inc. (NASDAQ:MIRA) Decreases By 31.4%
by Amy Steele · The Cerbat GemMIRA Pharmaceuticals, Inc. (NASDAQ:MIRA – Get Free Report) was the recipient of a large decrease in short interest during the month of December. As of December 15th, there was short interest totaling 187,740 shares, a decrease of 31.4% from the November 30th total of 273,552 shares. Approximately 0.5% of the shares of the stock are sold short. Based on an average daily volume of 194,579 shares, the days-to-cover ratio is currently 1.0 days. Based on an average daily volume of 194,579 shares, the days-to-cover ratio is currently 1.0 days. Approximately 0.5% of the shares of the stock are sold short.
MIRA Pharmaceuticals Trading Down 2.0%
NASDAQ MIRA traded down $0.03 during trading on Monday, hitting $1.48. The company had a trading volume of 171,078 shares, compared to its average volume of 249,107. The company’s fifty day moving average is $1.49 and its 200-day moving average is $1.44. MIRA Pharmaceuticals has a one year low of $0.73 and a one year high of $2.45. The company has a market cap of $61.98 million, a price-to-earnings ratio of -0.97 and a beta of 1.79.
MIRA Pharmaceuticals (NASDAQ:MIRA – Get Free Report) last released its earnings results on Thursday, November 13th. The company reported ($1.18) EPS for the quarter, missing analysts’ consensus estimates of ($0.11) by ($1.07). As a group, equities analysts anticipate that MIRA Pharmaceuticals will post -0.6 EPS for the current year.
Analyst Ratings Changes
MIRA has been the topic of a number of recent research reports. Weiss Ratings reiterated a “sell (e+)” rating on shares of MIRA Pharmaceuticals in a research report on Monday, December 22nd. Wall Street Zen cut MIRA Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Saturday, November 22nd. One research analyst has rated the stock with a Sell rating, According to data from MarketBeat, MIRA Pharmaceuticals presently has a consensus rating of “Sell”.
Get Our Latest Stock Report on MIRA Pharmaceuticals
Institutional Trading of MIRA Pharmaceuticals
A number of hedge funds have recently made changes to their positions in the stock. International Assets Investment Management LLC bought a new stake in MIRA Pharmaceuticals during the second quarter valued at about $42,000. Creative Planning bought a new position in shares of MIRA Pharmaceuticals in the second quarter worth about $27,000. XTX Topco Ltd purchased a new stake in shares of MIRA Pharmaceuticals during the second quarter worth about $26,000. First American Bank raised its stake in MIRA Pharmaceuticals by 150.0% during the 3rd quarter. First American Bank now owns 50,000 shares of the company’s stock valued at $68,000 after purchasing an additional 30,000 shares during the period. Finally, Two Sigma Investments LP raised its stake in MIRA Pharmaceuticals by 129.8% during the 3rd quarter. Two Sigma Investments LP now owns 45,703 shares of the company’s stock valued at $62,000 after purchasing an additional 25,816 shares during the period. 35.16% of the stock is owned by institutional investors.
MIRA Pharmaceuticals Company Profile
MIRA Pharmaceuticals, Inc operates as a pre-clinical-stage pharmaceutical development company with two neuroscience programs targeting a range of neurologic and neuropsychiatric disorders. The company holds exclusive U.S., Canadian, and Mexican rights for Ketamir-2, a patent pending oral ketamine analog under investigation to deliver ultra-rapid antidepressant effects for individuals battling treatment-resistant depression, major depressive disorder with suicidal ideation, and post-traumatic stress disorder.